Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and Zepbound microdosing. All providers are board-certified and design personalized tirzepatide protocols.
The single most common reason patients stop tirzepatide (Zepbound) is gastrointestinal intolerance — nausea, vomiting, and diarrhea that emerge during the standard dose-escalation phase. Yet the SURMOUNT-1 trial data shows that even the lowest active dose of tirzepatide — 5 mg weekly — produces a 15% average body weight reduction over 72 weeks. The clinical insight is straightforward: a lower dose, consistently maintained, produces better long-term outcomes than a higher dose abandoned due to side effects.
Physician-guided Zepbound microdosing applies this principle directly. Rather than advancing through doses on a fixed schedule, your board-certified physician calibrates your dose escalation to your individual tolerance — moving slower, holding at intermediate doses longer, or establishing a lower maintenance dose after you reach your target weight. The result is a tirzepatide program you can sustain, not one you have to quit.[1]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 6, 2026
If you tried tirzepatide or semaglutide and stopped because of nausea or GI discomfort, a physician-supervised microdosing re-entry protocol allows you to restart at a dose your system can tolerate — often 2.5 mg held for 8–12 weeks before any advancement — rebuilding the treatment you already know produces results.
After reaching your target weight, a full therapeutic dose may be unnecessary and expensive. Your physician can transition you to a lower maintenance dose — enough to preserve your results with reduced cost and side-effect burden. SURMOUNT-4 data confirms continued tirzepatide prevents the significant weight regain seen after full discontinuation.
If you have documented GI sensitivity, IBS, or a history of medication intolerance, starting tirzepatide on a conservative, extended titration schedule — rather than the standard 4-week escalation — significantly reduces the probability of early discontinuation. Your physician will build a ramp-up schedule calibrated to your specific risk profile.
Three landmark randomized controlled trials in the New England Journal of Medicine form the evidence base for FDA-approved GLP-1 weight management medications:
Telehealth prescribing of GLP-1 medications is fully legal in all 50 states when conducted by a properly licensed physician through a HIPAA-compliant platform. GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are not DEA-scheduled controlled substances — no in-person visit is required by federal or state telehealth law.
SURMOUNT-1 (NEJM 2022, n=2,539) tested three active doses of tirzepatide over 72 weeks. Here is the documented outcome at each level:
The lowest active dose in SURMOUNT-1 produced a 15% average body weight reduction at 72 weeks. 85% of participants at 5 mg lost at least 5% of their body weight. For many patients — particularly those on a microdosing or maintenance protocol — this dose delivers clinically significant, sustainable results with a markedly better side-effect profile than higher doses.
At 10 mg, SURMOUNT-1 participants achieved a 19.5% average weight reduction. 89% lost at least 5%, and 75% lost at least 10%. This intermediate dose offers a meaningful efficacy step-up from 5 mg for patients who tolerate escalation, and may serve as the target maintenance dose for patients who find 15 mg causes persistent side effects.
The highest dose in SURMOUNT-1 achieved 20.9% average loss in the full 15 mg group and 22.5% in the highest-dose subgroup — the greatest documented weight reduction of any FDA-approved GLP-1 medication. For patients who tolerate full escalation, 15 mg represents the maximum efficacy ceiling. Your physician determines whether this target is appropriate for your clinical profile.
Fill out our comprehensive health intake — covering your GI history, any prior GLP-1 experience, current medications, BMI, and weight goals. If you previously stopped tirzepatide or semaglutide due to side effects, document that experience in detail. This information directly shapes your microdosing protocol.
A board-certified physician reviews your profile via HIPAA-secure telehealth and prescribes a tirzepatide dosing schedule calibrated to your tolerance. This may mean starting at 2.5 mg and holding for 8–12 weeks before any escalation, targeting a specific intermediate dose as your long-term maintenance level, or re-entering at a low dose after a previous discontinuation.
Your prescribed tirzepatide ships from a PCAB-accredited compounding pharmacy directly to your door within 2–5 business days. Regular telehealth check-ins track your tolerance and progress — allowing your physician to advance, hold, or adjust your dose based on your real response data, not a fixed calendar schedule.
Connect with experienced, US-licensed physicians specializing in metabolic health and Zepbound microdosing. All providers are board-certified and design personalized tirzepatide protocols.
Adult obesity rates (CDC Behavioral Risk Factor Surveillance System, 2023) vary significantly across the United States. States with higher obesity prevalence experience the greatest demand for accessible GLP-1 telehealth prescriptions:
Source: CDC Behavioral Risk Factor Surveillance System (BRFSS) 2023. Adult obesity defined as BMI ≥ 30.0.
Select your state to connect with board-certified physicians who prescribe individualized, tolerance-calibrated tirzepatide protocols via telehealth — wherever you live.
Zepbound microdosing refers to starting tirzepatide at doses lower than the standard clinical escalation schedule — often 2.5 mg weekly, extended over a longer ramp-up period, rather than advancing to 5 mg, 10 mg, or 15 mg on the standard 4-week schedule. This approach is used by physicians to minimize gastrointestinal side effects (nausea, vomiting, diarrhea), which are the primary reason patients discontinue GLP-1 therapy. A slower, lower titration preserves the therapeutic benefit while giving the body more time to adapt. Your prescribing physician determines the appropriate protocol for your individual tolerance profile.
Yes. In the SURMOUNT-1 trial (NEJM 2022, n=2,539), even the lowest active dose of tirzepatide — 5 mg weekly — produced a 15% average body weight reduction at 72 weeks. The 10 mg dose produced 19.5%, and the 15 mg dose produced 20.9–22.5%. A physician-guided microdosing protocol that keeps you at a tolerable dose consistently will outperform a standard-dose approach you discontinue due to side effects. Sustainable lower dosing beats abandoned higher dosing.
Zepbound microdosing is most commonly considered for three patient profiles: (1) Patients who previously discontinued tirzepatide or semaglutide due to intolerable gastrointestinal side effects — microdosing allows re-entry at a tolerable level; (2) Patients transitioning to a maintenance phase who want to reduce costs and side effect burden while preserving results; (3) First-time GLP-1 patients with documented GI sensitivity who want a conservative start. Your board-certified physician will evaluate your specific clinical profile before recommending any dosing approach.
The FDA-approved tirzepatide (Zepbound) label specifies a standard escalation schedule starting at 2.5 mg weekly. "Microdosing" refers to physician-directed protocols that deviate from or extend this standard schedule — a legal and common practice under a licensed physician's medical judgment. Your board-certified physician prescribes the dose and schedule appropriate for your clinical situation. All prescriptions are for FDA-approved tirzepatide dispensed by licensed, PCAB-accredited compounding pharmacies.
Long-term weight maintenance with GLP-1 therapy is an active area of clinical research. Physicians increasingly use individualized, lower maintenance doses — sometimes below the standard trial doses — to sustain results at reduced cost and side effect burden after patients reach their target weight. The 2022 SURMOUNT-4 extension study demonstrated that continued tirzepatide significantly reduces weight regain vs. discontinuation. Your physician will discuss a long-term maintenance strategy calibrated to your goals and metabolic history.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
